IL156781A0 - (diazolo-pyridinyl)-pyrimidines for use in teatment of cns disorders and diabetes - Google Patents

(diazolo-pyridinyl)-pyrimidines for use in teatment of cns disorders and diabetes

Info

Publication number
IL156781A0
IL156781A0 IL15678102A IL15678102A IL156781A0 IL 156781 A0 IL156781 A0 IL 156781A0 IL 15678102 A IL15678102 A IL 15678102A IL 15678102 A IL15678102 A IL 15678102A IL 156781 A0 IL156781 A0 IL 156781A0
Authority
IL
Israel
Prior art keywords
diazolo
teatment
pyrimidines
pyridinyl
diabetes
Prior art date
Application number
IL15678102A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL156781A0 publication Critical patent/IL156781A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
IL15678102A 2001-02-20 2002-02-18 (diazolo-pyridinyl)-pyrimidines for use in teatment of cns disorders and diabetes IL156781A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0100569A SE0100569D0 (sv) 2001-02-20 2001-02-20 New compounds
PCT/SE2002/000271 WO2002065979A2 (en) 2001-02-20 2002-02-18 (diazolo-pyridinyl)-pyrimidines for use in treatment of cns disorders and diabetes

Publications (1)

Publication Number Publication Date
IL156781A0 true IL156781A0 (en) 2004-02-08

Family

ID=20283059

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15678102A IL156781A0 (en) 2001-02-20 2002-02-18 (diazolo-pyridinyl)-pyrimidines for use in teatment of cns disorders and diabetes

Country Status (23)

Country Link
US (1) US7345050B2 (sv)
EP (1) EP1373266A2 (sv)
JP (1) JP4475869B2 (sv)
KR (1) KR20030084935A (sv)
CN (1) CN1294131C (sv)
BG (1) BG108070A (sv)
BR (1) BR0206935A (sv)
CA (1) CA2434648A1 (sv)
CZ (1) CZ20032235A3 (sv)
EE (1) EE200300400A (sv)
HK (1) HK1070071A1 (sv)
HU (1) HUP0303254A2 (sv)
IL (1) IL156781A0 (sv)
IS (1) IS6868A (sv)
MX (1) MXPA03007320A (sv)
NO (1) NO20033679D0 (sv)
NZ (1) NZ526783A (sv)
PL (1) PL363393A1 (sv)
RU (1) RU2003121307A (sv)
SE (1) SE0100569D0 (sv)
SK (1) SK10252003A3 (sv)
WO (1) WO2002065979A2 (sv)
ZA (1) ZA200306171B (sv)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
AU2003208479A1 (en) 2002-03-09 2003-09-22 Astrazeneca Ab 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
US20080207594A1 (en) 2005-05-04 2008-08-28 Davelogen Aktiengesellschaft Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
UY29827A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones
WO2007040436A1 (en) * 2005-10-03 2007-04-12 Astrazeneca Ab Use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer’s disease
DE602006021645D1 (de) 2005-11-15 2011-06-09 Array Biopharma Inc Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
JP2010518014A (ja) * 2007-01-31 2010-05-27 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用な２−アミノピリジン誘導体
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
ES2524259T3 (es) * 2008-03-24 2014-12-04 Novartis Ag Inhibidores de metaloproteinasa de matriz a base de arilsulfonamida
US8344018B2 (en) 2008-07-14 2013-01-01 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
US8134000B2 (en) 2008-07-14 2012-03-13 Gilead Sciences, Inc. Imidazolyl pyrimidine inhibitor compounds
US8124764B2 (en) 2008-07-14 2012-02-28 Gilead Sciences, Inc. Fused heterocyclyc inhibitor compounds
US8088771B2 (en) 2008-07-28 2012-01-03 Gilead Sciences, Inc. Cycloalkylidene and heterocycloalkylidene inhibitor compounds
US9101645B2 (en) 2008-10-22 2015-08-11 Genentech, Inc. Modulation of axon degeneration
CA2761064A1 (en) 2009-04-15 2010-10-21 Astrazeneca Ab Imidazole substituted pyrimidines useful in the treatment of glycogen synthase kinase 3 related disorders such as alzheimer's disease
NZ596783A (en) 2009-06-08 2014-01-31 Gilead Sciences Inc Cycloalkylcarbamate benzamide aniline hdac inhibitor compounds
JP5586692B2 (ja) 2009-06-08 2014-09-10 ギリアード サイエンシーズ， インコーポレイテッド アルカノイルアミノベンズアミドアニリンｈｄａｃインヒビター化合物
KR102414221B1 (ko) 2020-08-04 2022-06-27 서울시립대학교 산학협력단 열전 소자 어셈블리, 이의 제조 방법, 및 이를 포함하는 열전 모듈

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE29032E (en) * 1969-06-12 1976-11-09 Riker Laboratories, Inc. 3-Benzoylfluoro-methanesulfonanilides
FR2179493A1 (en) * 1972-04-10 1973-11-23 Roussel Uclaf Amino benzhydrols - choleretics anticonvulsants sedatives and barbiturate potentiators
DE3042466A1 (de) * 1980-11-11 1982-06-16 A. Nattermann & Cie GmbH, 5000 Köln N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (sv) * 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9701453D0 (en) * 1997-01-24 1997-03-12 Leo Pharm Prod Ltd Aminobenzophenones
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
JP2004527486A (ja) 2004-09-09
EP1373266A2 (en) 2004-01-02
CN1537112A (zh) 2004-10-13
BR0206935A (pt) 2004-06-29
NO20033679L (no) 2003-08-19
CZ20032235A3 (cs) 2004-01-14
BG108070A (bg) 2004-07-30
WO2002065979A3 (en) 2003-02-20
KR20030084935A (ko) 2003-11-01
EE200300400A (et) 2003-12-15
NO20033679D0 (no) 2003-08-19
US7345050B2 (en) 2008-03-18
PL363393A1 (en) 2004-11-15
WO2002065979A2 (en) 2002-08-29
US20040077642A1 (en) 2004-04-22
JP4475869B2 (ja) 2010-06-09
SK10252003A3 (sk) 2004-02-03
CA2434648A1 (en) 2002-08-29
HUP0303254A2 (hu) 2004-01-28
IS6868A (is) 2003-07-08
RU2003121307A (ru) 2005-02-27
HK1070071A1 (en) 2005-06-10
MXPA03007320A (es) 2003-12-04
SE0100569D0 (sv) 2001-02-20
ZA200306171B (en) 2004-11-08
NZ526783A (en) 2005-04-29
CN1294131C (zh) 2007-01-10

Similar Documents

Publication Publication Date Title
IL156781A0 (en) (diazolo-pyridinyl)-pyrimidines for use in teatment of cns disorders and diabetes
HK1109867A1 (en) Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders
AU2002357676A1 (en) Use of somatostatin receptor agonists in the treatment of human disorders of sleep hypoxia and oxygen deprivation
HUP0200502A3 (en) Recombinant il-18 antagonists useful in treatment of il-18 mediated disorders
EP1450837A4 (en) INTERLEUKIN-1 RECEPTORS IN THE TREATMENT OF DISEASES
IL156865A0 (en) D-amino acid oxidase and d-aspartate oxidase for use in cns disorders
IL160853A0 (en) Nicotine containing formulations and use thereof
AU2003255993A1 (en) Diazabicyclic compounds useful in the treatment of cns and other disorders
HUP0303344A3 (en) Carbamate compounds for use in preventing and treating movement disorders
EP1492510A4 (en) LOW-DOSED LIQUID ENTECAVIR FORMULATIONS AND USE
IL157593A0 (en) Carbamate compounds for use in the treatment of pain
IL160018A0 (en) Isoxazolopyridinones and use thereof in the treatment of parkinson's disease
AU2002362115A8 (en) Composition and methods for treatment of neurological disorders
GB0128674D0 (en) Treatment of sleep disorders and the like
IL163926A0 (en) Crystal structure of phosphodiesterase 5 and use thereof
HUP0402326A3 (en) Pharmaceutical composition for prevention of addiction in pain management
AU2001248971A1 (en) Use of npy y1 receptor agonists in the treatment of pain conditions
EP1371371A4 (en) USE OF N-ACETYL-D-GLUCOSAMINE IN THE PRODUCTION OF A PHARMACEUTICAL AGENT FOR THE PREVENTION AND TREATMENT OF SEXUAL DISORDERS
EP1406720A4 (en) BUFFERS FOR ELECTROPHORESIS AND USE THEREOF
IL161388A0 (en) Method of reducing type 2 diabetes in high risk patients
GB0130248D0 (en) Delivering content
AU2002328173A1 (en) Omoxin agonists and antagonists for use in the treatment of metabolic disorders
AU2002339682A1 (en) Emergen agonists and antagonists for use in the treatment of metabolic disorders
IL161441A0 (en) Pathway of rantes-mediated chemokine synthesis in astrocytes and method of use therefor
AU2002334250A1 (en) Xafinix agonists and antagonists for use in the treatment of metabolic disorders